In rheumatoid arthritis (RA) inflammation causes joint destruction, [1] [2] [3] but disconnection between inflammation and destruction has also been described. [4] [5] [6] [7] [8] [9] [10] Although several studies have evaluated the relation between inflammation and destruction, it has never been quantified to what proportion the variance in joint destruction is accounted for by cumulative doses of inflammation. Therefore, we evaluated the variance in severity of joint destruction on hands and feet radiographs after 5 years of disease (Sharp-van-der-Heijde method, SHS) that is contributed by a cumulative dose of inflammation over this period. Ethical approval was obtained from the local ethical committee and all included patients gave their informed consent.
The cumulative inflammatory burden was estimated using the area under the curve of 3-monthly measured C reactive protein levels (AUC CRP ). First, 278 RA patients (1987 ACR criteria) with 2692 CRP measurements and with radiographs at 5-year follow-up of the Leiden Early-Arthritis-Clinic 10 were studied. Second, 911 CRP measurements obtained from 74 Groningen 11 RA patients with radiographs at 4, 5, 6 or 7 years follow-up (depending on the availability of the radiographs) were studied as replication cohort. This study period was chosen since a substantial number of Groningen patients had no radiograph exactly at year 5. Severity of joint destruction was measured by the difference between the SHS at baseline and at year 5. The explained variance in SHS (r 2 ) was calculated using linear regression with AUC CRP as an independent variable and radiological progression between inclusion and year 5 as a dependent variable. Since CRP does not measure local inflammation, we examined how much extra variance was explained by adding information on yearly swollen joint counts (AUC SJC ). Finally, data on anti-cyclic citrullinated peptide (CCP) antibodies were included.
In both datasets, the AUC CRP was associated with the severity of progression of joint destruction ( p<0.001). The variance of progression of joint destruction explained by AUC CRP was 19% and 15%, respectively (table 1). Subanalysis on RA patients who received no or delayed mild DMARD therapy showed the largest r 2 , 25% and 24%, respectively (figure 1). In the Leiden RA patients, the AUC SJC explained 8% of the variance in joint destruction progression, the combination of AUC SJC and AUC CRP explained 23%, and the combination of AUC CRP , AUC SJC and anti-CCP explained 40% of the variance in joint destruction progression.
This study has several limitations. We used only part of the RA patients included in the early arthritis clinic (EAC), namely those with radiographs at 5-years follow-up. However, baseline characteristics of included and excluded patients were not different (data not shown). Furthermore, the AUC CRP based on 3-monthly CRP measurements is an approximation of the true cumulative inflammatory burden. Therefore, the additional effect of AUC SJC was considered, though SJCs were assessed only yearly. The Disease Activity Score was not studied because some of its components do not entirely represent inflammation. Another limitation is that the second dataset was relatively small. Next, causality cannot be established from the present association study. Finally, the r 2 is a relative measure and depends on the total variance in the data. Nonetheless, the findings were comparable in two independent cohorts and sensitivity analyses on different follow-up durations in the Leiden-EAC showed comparable r 2 s (data not shown). A strength is the evaluation of untreated or mildly treated RA patients; their disease course may approximate the natural course. Figure 1 Variance of joint destruction explained by cumulative inflammation in Leiden and Groningen rheumatoid arthritis patients stratified by treatment strategy. DMARD, disease modifying anti-rheumatic drugs; EAC, early arthritis clinic; SHS, Sharp-van-der-Heijde method.
In conclusion, the variance in joint destruction explained by cumulative inflammation was moderate. This suggests that the severity of joint destruction is to a considerable extent driven by factors that are not related to inflammation as expressed using CRP or SJC.
In the Leiden RA patients (70% female subjects, mean±SD age 54±14 years, 66% anti-CCP2 positive), the mean SHS at 5 years was 26 and the variance 1063. In the Groningen RA patients (73% female subjects, mean±SD age 51±12 years), the mean SHS at the end of the study was 43 and the variance 2190.
The variance in joint destruction is presented that is explained by the cumulative measures of inflammation for different treatment strategies separately. Treatment of the Leiden RA patients differed for different inclusion periods (see also 11 ). In short, patients included between 1993 and 1996 were initially treated with non steroid anti-inflammatory drugs (NSAIDs), patients included between 1996 and 1998 were initially treated with mild disease modifying anti-rheumatic drugs (DMARDS) (chloroquine or sulphasalazine), and patients included from 1999 onwards were promptly treated with methotrexate or sulphasalazine. Groningen RA patients included before 1990 received initial NSAIDs before starting mild DMARD therapy, in contrast to the patients included after 1990 who started with DMARD therapy directly.
In the Leiden RA patients, the mean SHS at 5 years in the three groups was 39.9, 31.2 and 16, respectively. The variance in these three groups was 1725, 1234 and 435.5, respectively. The mean SHS and variance in the Groningen patients without DMARD treatment was 333 and 221 and with treatment 3152 and 923, respectively. 
